

HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

SPINRAZA®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 801-213-1547.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have medical pharmacy prior authorization questions, please call for assistance: 833-981-0212

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Spinraza® (nusinersen)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of spinal muscular atrophy (SMA) type 1, 2 or 3?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the requesting provider a neurologist with expertise in spinal muscular atrophy?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does clinical documentation show one of the following: <ul style="list-style-type: none"> • 5q SMA homozygous gene deletion or mutation • Compound heterozygote mutation 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Is the member ≤15 years of age?	<input type="checkbox"/>	<input type="checkbox"/>	
5. Is the member dependent on either invasive ventilation or tracheostomy?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Does documentation contain a baseline platelet count?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Does documentation include at least one of the following baseline motor ability scores: <ul style="list-style-type: none"> • Hammersmith Infant Neurological Exam (HINE) • Hammersmith Functional Motor Scale Expanded (HFMSE) • Upper Limb Module Test (non-ambulatory) • Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Has the member received treatment with Zolgensma®?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
9. Does clinical documentation show trial and failure or contraindication/intolerance to Evrysdi® (risdiplam)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

10. Is member currently taking Evrysdi® (risdiplam) or are there plans to start Evrysdi® (risdiplam)?			
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 7 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member meet initial authorization criteria?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the member received treatment with Zolgensma®?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does documentation show platelet counts prior to each dose?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Has the member responded to therapy with documentation showing maintenance or improvement in motor milestones?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-HU-M007
 Origination Date: 01/01/2022
 Reviewed/Revised Date: 05/22/2024
 Next Review Date: 05/22/2025
 Current Effective Date: 06/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.